

IMPROVEMENT OF THE CLINICAL, NUTRITIONAL AND INFAMMATORY PARAMETERS DURING HIGH FLUX HEMODIALYSIS

Authors: A.Sikole, S.Gelev, P.Dz.Vidimliski, I.R.Busletik, Gj.Selim, L.Trajeska

University Clinic of Nephrology, Skopje, Macedonia

OBJECTIVES

To investigate the beneficial effect of high-flux (HFHD) vs. low-flux (LFHD) dialysis on clinical findings in dialysis patients.

METHODS

Comparative analysis on dialysis and laboratory data was done in one arm crossover study. 65 patients were dialyzed 2 years on Low Flux and then crossed on High Flux dialysis for 2 years.

RESULTS

Study group characteristics		Comparative analysis - Dialysis variables-			
N=65	Mean ± St.Dev / (%)				
Age (years)	53.86 ± 11.49				
Vintage (months)	87.00 ± 72.82				
men	30 (46%)				
DM	7 (11%)				
Nutritional Indices					
N=65	Low Flux Mean ± St.Dev	High Flux Mean ± St.Dev		Sig.(p)	
Appetite score (1-5)	3.66 ± 0.98	4.17 ± 0.98		0.0001	
Body weight post HD (Kg)	63.49 ± 13.73	62.67 ± 13.18		0.079	
BMI (Kg/m ²)	25.00 ± 6.26	24.68 ± 6.069		0.088	
IDWG (Kg)	3.09 ± 0.76	3.23 ± 0.92		0.144	
Total Proteins (g/L)	69.87 ± 3.98	68.9 ± 5.33		0.092	
Albumin(g/L)	38.72 ± 2.94	38.50 ± 3.99		0.586	
s.Creatinine (μmol/L)	957.18 ± 374.06	976.55 ± 261.85		0.623	
Anemia management					
N=65	Low Flux Mean ± St.Dev	High Flux Mean ± St.Dev		Sig.(p)	
Hb (g/L)	115.80 ± 11.29	118.6 ± 9.11		0.040	
Htc	0.34 ± 0.03	0.36 ± 0.03		0.002	
Mean Weekly EPO Dosage (IU/week)	2687.76 ± 2314.97	2513.75 ± 2223.74		0.105*	
Mean Weekly EPO Dosage per Body Weight (IU/week/Kg)	44.65 ± 40.86	43.39 ± 40.50		0.197*	
Mean Weekly EPO Dosage per Body Weight per gram Hb (IU/week/Kg/g)	0.41 ± 0.37	0.38 ± 0.37		0.057*	
Iron metabolism					
N=65	Low Flux Mean ± St.Dev	High Flux Mean ± St.Dev		Sig.(p)	
Iron (μmol/L)	11.82 ± 4.10	12.90 ± 4.50		0.027	
TIBC (μmol/L)	39.21 ± 6.36	41.11 ± 7.23		0.006	
Transferin (g/dL)	30.82 ± 11.216	34.85 ± 25.08		0.396	
Ferritin (mg/L)	443.12 ± 200.01	500.84 ± 271.75		0.200	
Lipids and glycaemia					
N=65	Low Flux Mean ± St.Dev	High Flux Mean ± St.Dev		Sig.(p)	
Total Lipids (g/L)	7.92 ± 2.40	7.43 ± 1.44		0.031	
Cholesterol (mmol/L)	4.47 ± 1.07	4.32 ± 0.93		0.109	
HDL (mmol/L)	0.96 ± 0.41	1.16 ± 0.61		0.026	
LDL (mmol/L)	2.61 ± 0.95	2.38 ± 0.75		0.03	
Glicemia (mmol/L)	5.12 ± 1.17	5.61 ± 2.17		0.058	

- Urea Reduction ratio rose significantly ($p= 0.02$). In the HFHD the mean appetite score improved significantly from 3.66 to 4.17.
- The Hemoglobin level significantly rose from 115 to 118 g per liter in the HFHD.
- The level of total lipids significantly declined in the HFHD period from 7.92 to 7.43 g/L. The protective High-Density Lipids significantly rose from 0.96 to 1.16 and the Low-Density Lipids significantly declined from 2.61 to 2.38 mmol/L ($p<0.05$).
- The total calcium level significantly improved from 2.11 to 2.17 mmol /L. The phosphorous level did not change in spite the better appetite.
- We observed significant improvement in the leucocyte number and CRP level (6.82 ± 1.63 vs. 6.24 ± 1.62 , $p=0.0001$; 5.60 ± 5.14 vs. 4.40 ± 3.96 , $p=0.014$), respectively.

Mineral Bone Metabolism Indices, electrolytes and enzymes

N=65	Low Flux Mean ± St.Dev	High Flux Mean ± St.Dev	Sig.(p)
Ca (mmol/L)	2.11 ± 0.20	2.17 ± 0.25	0.005
Phosphorous (mmol/L)	1.54 ± 0.42	1.59 ± 0.46	0.259
PTH	548.49 ± 562.15	544.58 ± 528.62	0.957*
AP (U/L)	170.84 ± 261.54	218.82 ± 296.32	0.002*
Na (mmol/L)	142.50 ± 41.5	135.91 ± 17.1	0.208
K (mmol/L)	5.38 ± 0.61	5.24 ± 0.62	0.06
ALT (U/L)	22.58 ± 13.79	19.87 ± 10.98	0.029
AST (U/L)	19.64 ± 12.72	19.68 ± 14.30	0.971
N=65	Low Flux Mean ± St.Dev	High Flux Mean ± St.Dev	Sig.(p)
Le (x10 ⁹ /L)	6.82 ± 1.63	6.24 ± 1.62	0.0001
CRP (mg/L)	5.60 ± 5.14	4.40 ± 3.96	0.014*

Inflamatoty markers

CONCLUSIONS

High Flux Dialysis had beneficial effects on the nutritional, clinical and inflammatory parameters in dialysis patients.

References

Survival, Hospitalization and Quality of life for HD patients is still not optimal! Parker et al. Clin J Am Soc Nephrol 7: 1026–1032, 2012
Hemodiafiltration had no significant effect over Quality of Life over Time (CONTRAST) Mazariac et al. Clin J Am Soc Nephrol 8: 82–89, 2013

